NOVOZYMES NORTH AMERICA, INC.

Lobbying for NOVOZYMES NORTH AMERICA, INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$220,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

North Carolina

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 2756
National Biotechnology Initiative Act of 2025
S 1387
National Biotechnology Initiative Act of 2025
HR 7366
Dietary Supplement Regulatory Uniformity Act

Lobbying activity 3

Environment/Superfund

Issues related to renewables fuels and E-15 - no specific legislation.

Agriculture

Issues related to sustainability - no specific legislation. Issues related to animal feed additives, sustainability, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, and biological product in agriculture - no specific legislation. Issues related to biotechnology and biological products including H.R.2756/S.1387 - National Biotechnology Initiative Act of 2025. H.R. 7366 - Dietary Supplement Regulatory Uniformity Act - Issues related to dietary supplements.

Transportation

Issues pertaining to Supply Chain including movement of containers - no specific legislation. SHIP It Act (not yet introduced) - issues related to tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.